“The Applicant evaluated the safety of dordaviprone administered orally once or twice weekly in 28-day and 13-week GLP-compliant general toxicology studies using Sprague Dawley rats and Beagle dogs.”
✓ VerifiedFDA multi-discipline review, p. 37Source ↗
Why that species
Standard rodent and non-rodent species per ICH S9
“in both rodents (Sprague-Dawley rats) and nonrodents (Beagle dogs) (Studies ONC201-TX-100, ONC201-TX-101; m4.2.3.2). This program was consistent with ICH S9, the guideline for nonclinical evaluation for anticancer pharmaceuticals (ICH 2010).”
✓ VerifiedFDA multi-discipline review, p. 58Source ↗
Surrogate molecule
No surrogate; the clinical compound was tested
“The toxicity profile of orally administered dordaviprone was defined in GLP-regulated studies with once or twice (on 2 consecutive days) weekly administration for up to 13 weeks”
✓ VerifiedFDA multi-discipline review, p. 58Source ↗